We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Tempus AI: Revenue Mix and 2026 Growth Outlook Explained
Read MoreHide Full Article
Key Takeaways
TEM posted $693M in 2024 revenue, up 30% YoY, led by strong growth in Genomics and Data segments.
TEM achieved non-GAAP profitability in Q3, with EPS losses expected to narrow through 2026.
Revenue is projected to climb to $1.6B by 2026, driven by test volume growth and scaled data offerings.
Tempus AI (TEM - Free Report) operates at the intersection of clinical genomics and AI-driven insights. Its testing and data products are gaining traction with providers and biopharma partners. With revenue up sharply in 2024 and margins improving, investors are watching how its mix and execution translate into earnings power.
What Tempus AI Does and Why It Matters
Tempus AI is a healthcare technology company focused on advancing precision medicine through artificial intelligence. The company aggregates and structures multimodal clinical and lab data, then provides AI-enabled solutions to physicians, researchers, payers, and biopharma companies. Operating lines include Genomics and Data and services. Genomics spans oncology testing and hereditary testing, including DNA-based xT, liquid biopsy xF, and RNA-based xR assays used for therapy selection and disease monitoring. Hereditary testing addresses inherited cancer risk with broader rare disease coverage. Data and services commercialize de-identified datasets, clinical trial services, and analytics, supporting life sciences partners and provider use cases.
How Sales Are Trending
For 2024, Tempus generated about $693 million in revenue, up roughly 30% from 2023. Genomics contributed about $451.7 million, or around 65% of total, while Data and services delivered about $241.6 million, or 35%. The Sales Hist and Est visuals indicate a continuing ramp toward about $1.6 billion by 2026, with interim growth in 2025 supported by both testing volumes and scaled data products.
Profit Path and Earnings Quality
Management reached a key milestone by becoming profitable on a non-GAAP basis in the third quarter, aided by disciplined MRD expansion, ADLT progress and operating focus. GAAP EPS remains negative but is improving, with the EPS Hist and Est trajectory pointing toward a loss of 17 cents per share in 2027 after a deeper loss in 2024 and a narrower loss in 2025. The mix shift and operating leverage from the data platform underpin the path to better earnings over time.
Near-term Scorecard for Investors
Recent execution has been solid. The last EPS surprise was about 31%, while the last sales surprise was about 2.4%. Positive surprises of that magnitude can reinforce confidence in the scaling model and sustain interest from momentum-oriented holders. Conversely, a miss on either line could pressure sentiment given the premium growth profile and the market’s focus on operating leverage. With a catalyst calendar that includes regulatory and reimbursement milestones, quarterly prints may continue to drive outsized stock reactions.
Shares carry a Zacks Rank 3-Hold with Style Scores of Value F, Growth C, and Momentum B. The setup is neutral in the near term, with momentum screening better than valuation and growth. For investors using the Zacks framework, that combination argues for patience until estimate revisions or new datapoints tilt the risk-reward more decisively.
Risks to the Thesis
Key watch-items include reimbursement pressure relative to peers, the timing of regulatory processes that can shift near-term uplift, and persistent GAAP losses that can mask progress in underlying unit economics. Management also notes non-cash charges and moderating hereditary growth that temper the short-term impact from data catalysts. These factors could inject volatility into quarterly results even as the strategic direction remains intact.
Bottom line
Tempus AI’s dual-engine model is scaling, with genomics providing the base and AI-enabled data services broadening the opportunity set. The company crossed a non-GAAP profitability milestone, while consensus points to revenue compounding toward the billion-plus range by mid-decade and GAAP EPS trending toward breakeven by 2026. With a Rank 3-Hold and mixed Style Scores, the shares look balanced near term, leaving execution and surprise cadence as the swing factors for the next leg.
Peers to watch include Exact Sciences (EXAS - Free Report) , a major player in oncology diagnostics with a broad testing footprint, and Guardant Health (GH - Free Report) , which focuses on liquid biopsy and minimal residual disease. Both operate in adjacent markets that help frame competitive dynamics and adoption trends for precision oncology solutions. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Tempus AI: Revenue Mix and 2026 Growth Outlook Explained
Key Takeaways
Tempus AI (TEM - Free Report) operates at the intersection of clinical genomics and AI-driven insights. Its testing and data products are gaining traction with providers and biopharma partners. With revenue up sharply in 2024 and margins improving, investors are watching how its mix and execution translate into earnings power.
What Tempus AI Does and Why It Matters
Tempus AI is a healthcare technology company focused on advancing precision medicine through artificial intelligence. The company aggregates and structures multimodal clinical and lab data, then provides AI-enabled solutions to physicians, researchers, payers, and biopharma companies. Operating lines include Genomics and Data and services. Genomics spans oncology testing and hereditary testing, including DNA-based xT, liquid biopsy xF, and RNA-based xR assays used for therapy selection and disease monitoring. Hereditary testing addresses inherited cancer risk with broader rare disease coverage. Data and services commercialize de-identified datasets, clinical trial services, and analytics, supporting life sciences partners and provider use cases.
How Sales Are Trending
For 2024, Tempus generated about $693 million in revenue, up roughly 30% from 2023. Genomics contributed about $451.7 million, or around 65% of total, while Data and services delivered about $241.6 million, or 35%. The Sales Hist and Est visuals indicate a continuing ramp toward about $1.6 billion by 2026, with interim growth in 2025 supported by both testing volumes and scaled data products.
Profit Path and Earnings Quality
Management reached a key milestone by becoming profitable on a non-GAAP basis in the third quarter, aided by disciplined MRD expansion, ADLT progress and operating focus. GAAP EPS remains negative but is improving, with the EPS Hist and Est trajectory pointing toward a loss of 17 cents per share in 2027 after a deeper loss in 2024 and a narrower loss in 2025. The mix shift and operating leverage from the data platform underpin the path to better earnings over time.
Near-term Scorecard for Investors
Recent execution has been solid. The last EPS surprise was about 31%, while the last sales surprise was about 2.4%. Positive surprises of that magnitude can reinforce confidence in the scaling model and sustain interest from momentum-oriented holders. Conversely, a miss on either line could pressure sentiment given the premium growth profile and the market’s focus on operating leverage. With a catalyst calendar that includes regulatory and reimbursement milestones, quarterly prints may continue to drive outsized stock reactions.
Tempus AI, Inc. Price and Consensus
Tempus AI, Inc. price-consensus-chart | Tempus AI, Inc. Quote
What the Stock's Indicator Suggests
Shares carry a Zacks Rank 3-Hold with Style Scores of Value F, Growth C, and Momentum B. The setup is neutral in the near term, with momentum screening better than valuation and growth. For investors using the Zacks framework, that combination argues for patience until estimate revisions or new datapoints tilt the risk-reward more decisively.
Risks to the Thesis
Key watch-items include reimbursement pressure relative to peers, the timing of regulatory processes that can shift near-term uplift, and persistent GAAP losses that can mask progress in underlying unit economics. Management also notes non-cash charges and moderating hereditary growth that temper the short-term impact from data catalysts. These factors could inject volatility into quarterly results even as the strategic direction remains intact.
Bottom line
Tempus AI’s dual-engine model is scaling, with genomics providing the base and AI-enabled data services broadening the opportunity set. The company crossed a non-GAAP profitability milestone, while consensus points to revenue compounding toward the billion-plus range by mid-decade and GAAP EPS trending toward breakeven by 2026. With a Rank 3-Hold and mixed Style Scores, the shares look balanced near term, leaving execution and surprise cadence as the swing factors for the next leg.
Peers to watch include Exact Sciences (EXAS - Free Report) , a major player in oncology diagnostics with a broad testing footprint, and Guardant Health (GH - Free Report) , which focuses on liquid biopsy and minimal residual disease. Both operate in adjacent markets that help frame competitive dynamics and adoption trends for precision oncology solutions. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.